Clinical Trial Update: Safety Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain [Phase 2]

View source ↗

Summary

Phase 2 safety study of Aminolevulinic Acid (ALA) to enhance visualization and resection of brain tumors (glioma) has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Aminolevulinic acid (5-aminolevulinic acid)

Snippet

Sponsor: University of California, San Francisco | Conditions: Glioma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-29